Skip to main content
. Author manuscript; available in PMC: 2016 Nov 18.
Published in final edited form as: Nature. 2016 May 18;534(7606):272–276. doi: 10.1038/nature17963

Extended Data Figure 5. RapaLink-1 is a potent mTOR inhibitor in WT and mutant mTOR cells.

Extended Data Figure 5

a, MCF-7, (b) RR1, (c) RR2, (d) TKi-R cells were treated with different concentrations of rapamycin, MLN0128, combination treatment or RapaLink-1 over 3 days. The cell growth was determined as described in Figure 1d. Each dot and error bar on the curves represents mean ± standard deviation (n=8).